Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study

Ines Nikolovski1*, Maria I. Carlo2, Ying-Bei Chen3 and Hebert Alberto Vargas1

Abstract

Background: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a subtype of RCC that is increasingly recognized pathologically. The aim of this study was to evaluate the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography (FDG PET), and to determine the pre-operative diagnostic potential of imaging.

Methods: This single-site retrospective study included patients with histologically confirmed FH-RCC or with a renal cancer and known germline FH mutation; imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI, or FDG PET/CT between October 2007 and May 2019. Clinical information, pathological data, and imaging features were analyzed and reported descriptively.

Results: Sixteen patients with sixteen tumors were included (median age 46 years, interquartile range 38–53 years; 31 % female). Almost all tumors were unifocal (15/16, 94 %). Most tumors had infiltrative margins (14/16, 88 %); few were circumscribed (2/16, 12 %). A large cystic tumor component (> 75 % of tumor volume) was seen in 8/16 (50 %) of tumors. Involvement of renal sinus fat was seen in 13/16 (81 %) of tumors, involvement of the hilar collecting system in 8/16 (50 %), and renal vein tumor thrombus in 6/16 (38 %). All 12 tumors (100 %) imaged with MRI had heterogenous tumor enhancement and heterogenous T2 signal. Of those patients that had diffusion-weighted imaging, 11/11 (100 %) of tumors had diffusion restriction in the solid portions of the tumor. Of the patients who had PET, 3/3 (100 %) tumors showed high metabolic activity with mean maximum standardized uptake value (SUVmax) of 16.4 (range 9.6–21.9). Patients presented with retroperitoneal nodal metastases in 69 % of cases and distant metastases in 75 %. Of those four patients without metastatic disease at presentation, three (75 %) developed metastases within 4 years of diagnosis.

Conclusions: In our study, the majority of tumors (≥ 75 %) were unifocal, had an infiltrative margin, invaded the renal sinus fat, and presented with distant metastases. On MRI, most tumors had heterogenous T2 signal and diffusion restriction in their solid components. The small number of cases that had PET imaging showed high metabolic activity.

Keywords: FH-deficient, Hereditary leiomyomatosis and renal cell carcinoma syndrome, HLRCC

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Fumarate hydratase deficient renal cell carcinoma (FH-RCC) is a rare subtype of RCC. FH-RCC usually occurs in the context of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, an autosomal dominant disorder characterized by uterine and cutaneous leiomyomas and increased predisposition to an aggressive form of RCC [1]. HLRCC is caused by heterozygous germline mutations in the FH gene located on chromosome 1, which encodes FH, a critical component of the Krebs cycle [2, 3]. The mutations impair oxidative phosphorylation and lead to the accumulation of oncometabolites [4]. Recent work by Shuch et al. has found that FH alterations are more common than previously suspected and are carried by approximately 1 in 1000 individuals, however the lifetime kidney cancer penetrance appears lower than previously described, with an estimate based on one definition of carrier frequency ranging from 3.6 to 11.9% [5]. Since 2016, the World Health Organization classification of tumors of the urinary system has included HLRCC-associated RCC as a separate entity [6]. However, as opposed to HLRCC-associated RCC, less commonly, histologically indistinguishable tumors can also arise from biallelic somatic loss of FH, without the germline mutations denoting HLRCC syndrome.

FH-RCC has been described in the pathology literature as typically having FH-deficiency or 2-succino-cysteine (2SC) positive immunoreactivity on immunohistochemical (IHC) analysis, and can be distinguished histologically by papillary architecture with abundant eosinophilic cytoplasm, large nuclei, and very prominent nucleoli with perinucleolar clearing [7–9]. The imaging characteristics of FH-RCC, however, remain largely unknown, beyond the fact that these tumors are usually metastatic at presentation and typically solitary and unilateral, unlike other familial RCC syndromes that are characterized by bilateral multifocal tumors [10]. The lack of radiology literature available for FH-RCC is probably due to the fact that these tumors are uncommon compared with non-FH deficient RCC subtypes, and can be difficult to diagnose pathologically, requiring the pathologist to be vigilant when encountering renal masses with unusual or unclassified histologic features [11]. Knowledge of the clinical and pathologic characteristics of HLRCC has been expanding since it was first described twenty years ago, but it is still unknown whether there are any distinguishing imaging features that may allow for accurate preoperative diagnosis. Such imaging features have importance for both the individual patient and their extended family members given the often-aggressive nature of these tumors and the likelihood of a hereditary cancer syndrome. Imaging diagnosis may also assist the pathologist in ensuring confirmatory FH or 2-SC IHC analysis of the surgical specimen is performed, testing which is not routine in RCC.

The purpose of this study was to document the imaging features of FH-RCC on computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose positron emission tomography CT (FDG PET/CT) in order that these may aid in the prospective identification of patients who may be at risk of HLRCC and a more aggressive disease course.

Methods
The Institutional Review Board approved this retrospective, Health Insurance Portability and Accountability Act-compliant single-site study and waived written informed consent. The inclusion criteria for the study were (i) patient with a renal mass and presence of FH germline mutation, or a renal mass with FH loss and/or 2-succino-cysteine (2SC) positive immunoreactivity on IHC analysis, (ii) imaging of the renal mass before treatment with contrast-enhanced CT, contrast-enhanced MRI or FDG PET/CT, (iii) imaging study available in Digital Imaging and Communications in Medicine (DICOM) format through our institution’s picture archiving and communications system (PACS) and, (iv) imaging study performed between date range of 10/01/2007 and 05/01/2019. Sixteen patients satisfied all the above inclusion criteria.

The CT and MRI studies were a combination of in-house and outside studies performed on multiple different scanners. All studies included post-contrast images, and the MRI studies included standard abdominal sequences, with variability in scanner and protocol not affecting the qualitative features that were analyzed. All imaging studies were performed prior to histologic evaluation and genetic testing and reviewed retrospectively by a single genitourinary radiologist (IN) with 5 years of post-fellowship experience. For all CT and MRI studies, the radiologist documented tumor size, location,

| Characteristics                  | n (% ) |
|----------------------------------|--------|
| Total                            | 16     |
| Male                             | 11 (69)|
| Female                           | 5 (31) |
| Median age in years (Interquartile range) | 46 (38–53) |
| Germline FH mutation (HLRCC)     | 13 (81)|
| Somatic FH mutation              | 3 (19) |
| CT with contrast                 | 13     |
| MRI with contrast                | 12     |
| DWI                              | 11     |
| FDG PET/CT                       | 3      |
| Mean follow up time in months (range) | 26 (9–60) |

*FH fumarate hydratase, HLRCC hereditary leiomyomatosis and renal cell carcinoma, CT computed tomography, DWI diffusion-weighted imaging, FDG PET/CT fluorodeoxyglucose positron emission tomography*
focality, ill-defined or circumscribed margins, presence of large cystic tumor component (defined as greater than 75% tumor volume involved by component with fluid density on CT or signal intensity on MRI), invasion of renal sinus fat and/or collecting system, presence of peritumoral vascularity, presence and heterogeneity of enhancement, renal vein invasion, retroperitoneal nodal metastases (defined as lymph node measuring greater than 1 cm short axis and/or suspicious morphologic features such as rounded margin and heterogeneity), and distant metastases. Additional modality-specific tumor features were also recorded, such as presence of calcifications on CT, and presence of intravoxel fat, T1 hyperintense hemorrhage, T2 signal heterogeneity, and diffusion restriction on MRI. For PET, the presence of tumor FDG avidity above liver background and mean maximum standardized uptake value (SUV$_{\text{max}}$) were recorded.

**Results**

**Clinical features**

This study included 16 patients with 16 tumors. Patients ranged in age from 20 to 73 years (median 46 years, interquartile range 38–53 years); 11 patients were male, and 5 were female. Germline FH mutation was present in 13 patients indicating they had HLRCC (only 1 patient was aware of having HLRCC prior to presentation with FH-RCC), and the remaining 3 patients had somatic FH mutations only. The tumors were predominantly unilateral and solitary (15/16, 94%), apart from one patient who had bilateral multifocal tumors, of which only the largest tumor was analyzed. There was no predilection for kidney laterality. Thirteen patients had a CT scan with contrast, 12 had MRI with contrast (of those, 11 had diffusion-weighted images available for review), and three had an FDG PET/CT study. Clinical and demographic characteristics, and the number of cases of each imaging modality, are presented in Table 1.

### Table 2 Imaging Features of Fumarate Hydratase-Deficient Renal Cell Carcinoma

| Imaging Features                                      | n (%) |
|-------------------------------------------------------|-------|
| **Tumor Location and Size**                           |       |
| Left                                                  | 8 (50) |
| Right                                                 | 7 (44) |
| Bilateral                                             | 1 (6)  |
| Size mean centimeters (range)                         | 10.3 (2.2–18) |
| Size median centimeters                               | 9.8    |
| **General Tumor Features**                            |       |
| Unifocal                                              | 15 (94) |
| Multifocal bilateral                                  | 1 (6)  |
| Infiltrative margin                                   | 14 (88) |
| Circumscribed margin                                  | 2 (12) |
| Large cystic or necrotic component                    | 8 (50) |
| Involvement of renal sinus fat                        | 13 (81) |
| Involvement of hilar collecting system                | 8 (50) |
| Heterogenous enhancement                              | 16 (100)|
| Peritumoral vascularity                               | 9 (56) |
| Renal vein thrombus                                   | 6 (38) |
| Retroperitoneal nodal metastases                      | 11 (69) |
| Distant metastases at presentation                    | 12 (75) |
| No metastases at presentation                         | 4 (25) |
| **CT-Specific Tumor Features**                        |       |
| Calcifications                                        | 0      |
| **MRI-Specific Tumor Features**                       |       |
| T1 hemorrhage                                         | 7 (58) |
| Intravoxel fat                                        | 0      |
| T2 signal heterogeneity                               | 12 (100)|
| Diffusion restriction in solid component              | 11 (100)|
| **PET-Specific Tumor Features**                       |       |
| FDG avidity above liver background                    | 3 (100) |
| SUV$_{\text{max}}$ mean (range)                       | 16.4 (9.6–21.9) |

*CT computed tomography, MRI magnetic resonance imaging, DWI diffusion-weighted imaging, FDG PET fluorodeoxyglucose positron emission tomography, SUV$_{\text{max}}$ maximum standardized uptake value*
Fig. 2 46-year-old female with fumarate hydratase-deficient renal cell carcinoma. On magnetic resonance imaging, axial T2 single-shot fast spin echo (a) and post-contrast 3D fat-saturated T1-weighted (b) sequences show a left renal mass with large cystic component.

Fig. 3 38-year-old male with fumarate hydratase-deficient renal cell carcinoma (FH-RCC). On magnetic resonance imaging, axial post-contrast 3D fat-saturated T1-weighted sequence showing a left renal mass with heterogenous enhancement (a). 63-year-old male with FH-RCC, axial fat-suppressed T2-weighted sequence showing a right renal mass with heterogenous T2 signal (b).
Imaging features

Imaging findings are summarized in Table 2. Tumors ranged in size from 2.2 cm to 18 cm (mean 10.3 cm, median 9.8 cm) and had an infiltrative rather than circumscribed margin in the majority of cases (14/16, 88%) (Fig. 1). Regarding general tumor features, a large cystic tumor component involving greater than 75% of the tumor was seen in 8/16 (50%) of tumors (Fig. 2). Tumor invading the renal sinus fat was seen in 13/16 (81%) of tumors, hilar collecting system invasion in 8/16 (50%) (Fig. 1), and renal vein tumor thrombus in 6/16 (38%).

Regarding modality-specific features, all patients had heterogeneous tumor enhancement on MRI and CT, and heterogeneous T2 signal on MRI (Fig. 3). Of those patients who had diffusion-weighted imaging available for review (n = 11), all had diffusion restriction in the solid portions of the tumor. On MRI, T1 hyperintense hemorrhage was present in 7/12 (58%) of cases (Fig. 4). No tumors had intravoxel fat on MRI. On CT, no tumors had calcifications. Of the three patients who had an FDG PET/CT, all had high metabolic activity (mean SUV max 16.4, range 9.6–21.9), as shown in Fig. 5. An example of the gross and histologic features of one of the renal tumors is shown in Fig. 6.

At presentation, 11/16 (69%) of patients had retroperitoneal nodal metastases and 12/16 (75%) had distant metastases. Locations of distant metastases were the lung (n = 8), bone (n = 5), thoracic lymph nodes (n = 4), peritoneum (n = 1), pleura (n = 1), adrenal gland (n = 1), and liver (n = 1). Of the four patients who did not have metastatic disease at presentation, three (75%) developed metastases within four years of diagnosis. Within a mean follow-up period of 26 months (range 9 to 60 months), 9/16 patients (56%) died of disease. Only one patient did not have metastatic disease at time of writing, 4.5 years since diagnosis.
Discussion

FH-RCC is a rare subtype of RCC, and to our knowledge, this is the largest single case series to describe the imaging features of FH-RCC. Regarding the clinical features of FH-RCC, this case series confirms the findings described in several larger series in the pathology literature [8, 12–14] indicating that FH-RCC usually presents at an advanced stage and in a younger population than non-FH deficient RCC. In comparison with national United States Surveillance, Epidemiology, and End Results (SEER) for tumors of the kidney and renal pelvis, this case series had a median age of 46 years at diagnosis compared with 64 years, and 75% with distant metastases at presentation compared with 16% [15]. One of the largest series in the pathology literature presented by Merino et al. (38 patients with 40 tumors) reported histological findings that are similar to the imaging findings presented here. Their series had similar tumor sizes, ranging from 2.3 cm to 20 cm, which were predominantly unilateral and solitary with no predilection for laterality, and showed frequent capsular and perinephric fat invasion, frequent renal vein, and inferior vena cava invasion. They showed that 21/40 tumors in their study had at least a minor cystic component, compared to 50% of cases having a large (>75% of tumor volume) cystic component in this radiology case series [8].

The CT and MRI features of FH-RCC tumors in this case series appeared aggressive in most cases, illustrated by the presence of infiltrative rather than circumscribed margins, heterogeneity of MRI signal and enhancement, as well as renal sinus fat invasion. There were, however, no specific or unique features that would potentially allow them to be distinguished preoperatively from other non-FH deficient RCC on CT and MRI.

The three cases with FDG PET imaging all showed high metabolic activity within the renal mass. This feature is underpinned by tumor biology, as the FH-deficient cells have lost their ability to perform oxidative phosphorylation through the Krebs cycle, therefore depending on glycolysis, which is the basis of the Warburg effect in FDG PET imaging. There may therefore be a role for FDG PET/CT in the staging and assessment of treatment response in FH-RCC, and perhaps also in screening of asymptomatic patients with HLRCC. In contrast, typical non-FH deficient subtypes of RCC, such as clear cell RCC, are not usually considered Warburg tumors, and FDG PET has not been recommended as a routine imaging tool for RCC in professional practice guidelines [16, 17].

This study has limitations. It is a retrospective series of a small study population, and imaging with CT, MRI, and PET/CT was not available in all patients. While pathologists are becoming more aware of this entity, FH deficiency is not always tested for on IHC, and so the true scope of the imaging appearance of FH-RCC is unknown. Indeed, there is also a wider spectrum of pathologic findings in FH-RCC than previously thought, including a recently described low grade variant [18].

Conclusions

This case series documents the appearance of FH-RCC on CT, MRI, and FDG PET/CT. On CT and MRI, the majority of these masses had invasive features and could foreseeably appear similar to any advanced stage renal tumor, although there was no direct comparison between FH-RCC and non-FH deficient RCC made in this study. The atypical finding of high metabolic activity in FDG PET imaging needs to be explored further in larger cohorts, to determine whether this could be a way to differentiate FH-deficient RCC from non-FH-deficient RCC.
Abbreviations
2SC: 2-succino-cysteine; CT: Computed Tomography; DICOM: Digital Imaging and Communications in Medicine; FH: Fumarate hydratase; FH-RLCC: Fumarate hydratase-deficient renal cell carcinoma; FDG PET: Fluorodeoxyglucose positron emission tomography; HLRCC: Hereditary leiomyomatosis and renal cell carcinoma; IHC: Immunohistochemical; MRI: Magnetic Resonance Imaging; PACS: Picture Archive and Communication System; SEER: Surveillance, Epidemiology, and End Results; SUVmax: Maximum standardized uptake value

Acknowledgements
Not applicable.

Authors’ contributions
IN and HAV made substantial contributions to the conception and design of the study. IN reviewed all imaging studies, performed the statistical analysis and drafted the manuscript. MC, YBC, and HAV contributed to the conception of the work and substantively revised it. All authors agreed to participate and approved the submitted version.

Funding
This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The Institutional Review Board at Memorial Sloan Kettering Cancer Center approved this retrospective, HIPAA-compliant study and waived written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St #1407, NY 10065 New York, USA. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Received: 4 December 2020 Accepted: 9 February 2021
Published online: 19 February 2021

References
1. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98(6):3367–92.
2. Lehtonen HI, Kiuru M, Vyasukko-Oja SK, Salovaara R, Herva R, Kovisto PA, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006;43(6):523–6.
3. Tomlinson IPM, Alam NA, Rowan AJ, Barclay E, Jaeger EEM, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;32(4):406–10.
4. Moch H, Ohashi R, Gandhi JS, Amin MB. Morphological clues to the appropriate recognition of hereditary renal neoplasms. Semin Diagn Pathol. 2018;35(3):184–92.
5. Shuch B, Li S, Rishe H, Bindra RS, McGillivray PD, Gerstein M. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. Cancer. 2020;126(16):3657–66.
6. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93–105.
7. Ohe C, Smith SC, Sirohi D, Divata M, de Peralta-Venturina M, Paner GP, et al. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. Am J Surg Pathol. 2018;42(3):279–92.
8. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol. 2007;31(10):1578–85.
9. Chen YB, Brannon AR, Toubaj A, Dudas ME, Won HH, Al-Ahmade HA, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38(5):627–37.
10. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003;226(1):33–46.
11. Peng YC, Chen YB. Recognizing Hereditary Renal Cancers Through the Microscope: A Pathology Update. Surg Pathol Clin. 2018;11(4):725–37.
12. Pivovarikova K, Martinek P, Grossmann P, Tripkov K, Alaghebandian R, Magi-Galluzzi C, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical alteration analysis of 12 cases. Ann Diagn Pathol. 2019;39:63–8.
13. Muller M, Ferlicot S, Guillaud-Bataille M, Le Teuff G, Genestie C, Deveaux S, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers. Clin Genet. 2017;92(6):606–15.
14. Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, et al. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients. Am J Surg Pathol. 2020;44(1):98–110.
15. Cancer Statistics Review SEER. 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, 2020.
16. Yang Y, Valenta V, Sobrier C, Vocke CD, Wei M, Pike L, et al. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet. 2012;205(7–8):377–90.
17. Lindenberg L, Mena E, Choyke PL, Bouchelouche K. PET imaging in renal cancer. Curr Opin Oncol. 2019;31(3):216–21.
18. Smith SC, Sirohi D, Ohe C, McHugh JB, Hornick JL, Kalariya J, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma. Histopathology. 2017;71(1):42–52.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.